What is Bivalirudin?
Bivalirudin is a direct thrombin-inhibitor peptide used in procedural anticoagulation. The featured analysis examined patients with ST-elevation myocardial infarction undergoing coronary intervention.
Biological role or research focus
Procedural anticoagulation.
The composite comparison was not statistically significant. Access route, accompanying antiplatelet treatment, and subgroup context limit generalization to every procedure.
Role reference: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
- Class / identity
- Direct thrombin-inhibitor peptide
- Research focus
- Procedural anticoagulation
- Featured evidence
- Human randomized trial (prespecified subgroup)
- Source check
- October 4, 2026
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Quick answers
- Is Bivalirudin FDA approved?
- Yes. Angiomax (NDA 020873, approved 2000) and other bivalirudin products. Source ↗
- Is Bivalirudin safe?
- Hospital blood thinner used during artery-opening heart procedures; bleeding is the main risk, and it is not used in people who are actively bleeding. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Bivalirudin banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| VALIDATE-SWEDEHEART STEMI subgroup (2021) | Human randomized trial (prespecified subgroup) | 3,005 patients with ST-elevation myocardial infarction in a prespecified VALIDATE-SWEDEHEART subgroup. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial (prespecified subgroup) · 2021
VALIDATE-SWEDEHEART STEMI subgroup
Did death, myocardial infarction, or major bleeding differ versus heparin?
- Population / model
- 3,005 patients with ST-elevation myocardial infarction in a prespecified VALIDATE-SWEDEHEART subgroup.
- Study design
- Randomized comparison of bivalirudin with heparin; approximately 90% radial access; contemporary antiplatelet treatment; 180-day outcomes.
- Main finding
- The composite of death, myocardial infarction, or major bleeding occurred in 12.5% versus 13.0%: hazard ratio 0.95 (95% CI 0.78–1.17).
- Limits & context
- The composite comparison was not statistically significant. Access route, accompanying antiplatelet treatment, and subgroup context limit generalization to every procedure.
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
74 registered studies name Bivalirudin as an intervention; 6 are recruiting or under way, 2 have not started recruiting yet, 36 completed and 30 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 74 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Bivalirudin. ↗
· 2024 Jan · Study Guide
Bivalirudin. ↗
Thrombosis and haemostasis · 2008 May · Journal Article, Research Support, Non-U.S. Gov't, Review
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation. ↗
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2025 Jan 1 · Journal Article, Randomized Controlled Trial, Comparative Study
Read available full text ↗
Bivalirudin in Extracorporeal Membrane Oxygenation. ↗
Journal of cardiovascular pharmacology · 2024 Dec 1 · Journal Article, Review
Risks & interactions
Hospital blood thinner used during artery-opening heart procedures; bleeding is the main risk, and it is not used in people who are actively bleeding.
Safety comes from FDA-approved labeling based on large trials in patients undergoing artery-opening heart procedures (PCI). It is used only in hospital settings, so the label offers no safety data outside that context.
Take extra care with: Heart or blood pressure problemsBlood thinners or bleeding problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with active major bleeding
- People with a past allergic reaction (such as anaphylaxis) to bivalirudin or its components
Interactions
- Heparin, warfarin, clot-dissolving drugs or glycoprotein IIb/IIIa inhibitors: higher risk of major bleeding
Serious risks
- Major bleeding, including bleeding in the brain or behind the abdomen
- Sudden clotting of a newly placed stent in heart attack (STEMI) patients
- Clot formation, sometimes fatal, during coronary gamma brachytherapy
- Allergic reactions, including anaphylaxis
Common side effects
- bleeding
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: bivalirudin prescribing information ↗
What the featured evidence can tell us
Bleeding is a central consideration for anticoagulants. This subgroup analysis does not provide a personal treatment regimen or prove that bivalirudin is superior in every interventional setting.
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Identity, route, and evidence limits
The composite comparison was not statistically significant. Access route, accompanying antiplatelet treatment, and subgroup context limit generalization to every procedure.
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Official product context · checked October 4, 2026
Major active bleeding and hypersensitivity are contraindications in the linked label. Bleeding, acute stent thrombosis in certain procedural settings, and renal-function considerations require clinical oversight.
Source: DailyMed · Bivalirudin prescribing information · May 2025 ↗
Regulatory status
- U.S. FDA approval
- Approved
Angiomax (NDA 020873, approved 2000) and other bivalirudin products; anticoagulant used during percutaneous coronary intervention. Generics available. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
Bivalirudin is a prescription anticoagulant for percutaneous coronary intervention, including specified patients with heparin-induced thrombocytopenia. An approved procedural use is distinct from whether a particular trial proves superiority over heparin.
The selected analysis concerns anticoagulation during coronary intervention in a modern treatment setting. Product-specific indications and monitoring require current clinical references.
Source: DailyMed · Bivalirudin prescribing information · May 2025 ↗
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Bivalirudin works
Thrombin inhibition reduces clot formation. That pharmacological effect creates both a therapeutic purpose and a bleeding risk; it is not a general cardiovascular-health supplement.
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Molecular structure
Questions worth asking
- Did this analysis show fewer deaths, infarctions, or major bleeds overall?
- What population, comparator, and route were actually studied?
- The composite comparison was not statistically significant. Access route, accompanying antiplatelet treatment, and subgroup context limit generalization to every procedure.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did this analysis show fewer deaths, infarctions, or major bleeds overall?
The combined endpoint did not significantly differ. A nonsignificant result does not establish identical outcomes, and individual components require separate reading.
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction. · 2021 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
Source: DailyMed · Bivalirudin prescribing information · May 2025 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
